What’s happening now ? Epidemiology of (carbapenem) resistance Neil Woodford HPA – AMRHAI - Colindale The resistance ratchet keeps turning Pathogen Established problems Emerging threats E. faecium VRE, HLGR, Amp-R Lin-R, Dap-R, Tig-R S. aureus MRSA (ha/ca) Van-R, Lin-R, Dap-R Klebsiella ESBLs Carbapenemases, Col-R Acinetobacter MDR, Carbapenemases Tig-R, Col-R Pseudomonas MDR, except Col Carbapenemases, Col-R Enterobacter AmpC, ESBLs Carba-R, Carbapenemases E. coli Cip-R, ESBLs Carbapenemases • 5 of 7 ESKAPEEs are Gram-negative • Increasing reliance on carbapenems • Rising incidence of carbapenem resistance • The resistance issue for the next 5-10 years % Resistant E. coli from blood & CSF in the UK - a recent fall in resistance Hospital antibiotic sales (kg) IMS data 25000 20000 15000 Carbapenems Oxyimino cephs Amox clav Piptaz Fluoroquinolones 10000 5000 0 199819992000200120022003200420052006200720082009 • use of pip/taz, co-amoxiclav (& carbapenems) • new selective pressures ..., but what consequences ? Carbapenem non-susceptibility, 2011 (Ears-Net) E. coli K. pneumoniae • <1.5% non-susceptibility in E. coli as judged by surveys • 3 countries reported >5% non-susceptibility in K. pneumoniae http://ecdc.europa.eu/en/activities/surveillance/EARS-Net/database/Pages/database.aspx ...a worsening picture 70.8% 29.6% http://ecdc.europa.eu/en/activities/surveillance/EARS-Net/database/Pages/graph_report.aspx Canton et al, CMI 2012 Carbapenemase-producing Enterobacteriaceae in the UK (n = 1802) Imported & ‘home grown’ Early cases often imported Klebsiella spp. 79%; E. coli 12%, Enterobacter spp., 7%; others 2% AMRHAI, Unpublished data More labs are isolating ‘CPE’ in the UK 133 labs referred at least one isolate, 2003-2012 AMRHAI, Unpublished data Regional distribution of ‘CPE’ referrals, 2003-2012 KPC NDM OXA-48 VIM AMRHAI, Unpublished data Why isn’t ‘ST258’ K. pneumoniae a bigger problem in the UK? • The dominant KPC +ve lineage internationally • • • • 7 Several related STs Endemic in many parts of US, most of Greece Caused a nationwide outbreak in Israel Rapid, nationwide spread in Italy • First detected in UK in 2007 1 2 • Ongoing NIHR study (non-NW isolates) 1 3 1 2 3 0 1 4 3 • • • • 65/108 tested = ‘ST258 complex’ 42/82 ‘MLST-ed’ isolates are classic ST258 8/82 are its SLV, ST512 ≥1 isolate in most UK regions, …but over 6 years • Why not (yet) a major problem in the UK ? Findlay et al., Unpublished data Highly-related IncFII plasmids are spreading KPC in NW England 3 SNPs 2 SNPs 2 SNPs 1 SNPs pKpQIL-D1 3 SNPs pKpQIL-D2 1 SNPs Doumith et al., Unpublished data Non-fermenters with metallocarbapenemases in the UK (n = 393) Number P. aeruginosa Acinetobacter Pseudomonas spp. AMRHAI, Unpublished data More labs are isolating MBL +ve non-fermenters in the UK VIM +ve Pseudomonas, 2003-2012 98 labs referred at least one isolate, 2000-2012 AMRHAI, Unpublished data VNTR analysis of MBLproducing P. aeruginosa • 6 groups account for 85% (251/297) of MBL- positive isolates ST235 58 isolates, 28 labs • 25 ‘types’ in remaining 15% ST233 35 isolates, 16 labs ST773 21 isolates, 12 labs ST654 31 isolates, 13 labs ST111 90 isolates, 28 labs • do widely occurring strains represent true spread or just prevalence ? • horizontal spread of MBL genes ST357 16 isolates, 8 labs Wright et al., Unpublished data Advice on treatment when multi-resistance is the norm Metallo-enzyme Producers (IMP, NDM or VIM) ≥90% HPR, 2011; 5: issue 24 (17/06/11; Woodford & Livermore) Activity of colistin in vitro, carbapenemase +ve vs. -ve 80 60 E. coli 1-2% Col-R 40 + - 20 0 % isolates 0.125 0.25 0.5 1 2 4 8 16 32 80 60 Klebsiella 5-6% Col-R 40 + - 20 0 0.125 0.25 0.5 1 2 4 8 16 32 80 Enterobacter 5-6% Col-R 60 40 + 20 - 0 0.125 0.25 0.5 1 2 4 8 16 32 MIC, mg/L AMRHAI, Unpublished data Containing multi-resistant bacteria: the critical triangle Multi-disciplinary approach to limit risk and impact Outbreaks contained Effective IPC • microbiology • surveillance • infection prevention and control • diagnostics • drug development • diagnostic / reference / R&D / industrial partnerships Containing multi-resistant bacteria: the critical triangle Multi-disciplinary approach to limit risk and impact Outbreaks contained Effective IPC • microbiology • surveillance • infection prevention and control • diagnostics • drug development • diagnostic / reference / R&D / industrial partnerships ‘Resistance’ threatens the UK and the NHS every day Colonized residents or visitors Non-human reservoirs: foodstuffs (domestic or imported) Non-human reservoirs: animals and environment Hospital treatment or travel overseas Inter-hospital transfers (UK) Victims from conflict zones • Multiple risks to be assessed to minimize damage • Requires the detail to be understood • Continuous education of NHS staff at all levels Multi-pronged attack on resistance • Better intelligence (improved global surveillance initiatives) • Identify global hot spots / high risk patients • Inform damage limitation strategies... • Faster and more accurate diagnostics • Better infection prevention and control (public health) • More effective therapies (individuals) • Now...rational antibiotic use (right drug, right time, right regimen) • Future...a pipeline of new agents to overcome current problems Training Opportunities 21st March - Carbapenem resistance: how should we respond? (MIC Centre, Euston) 20th May – “A Crash Course on Carbapenem Resistance” (Colindale; pilot ½-day course for Greater London)